Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: A randomized trial

American Journal of Medicine

Volumn 114, Issue 5, 2003, Pages 347-353

  Owada, Akira ^a   Suda, Shin ^a   Hata, Toshihiko ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPOPROTEIN A; NICERITROL; NICOTINIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; URINARY EXCRETION;

EID: 0037396765     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01567-X     Document Type: Article

References (38)

1. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 330:1994;877-884.
2. A long term, randomised clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol. 3:1991;193-202.
3. Cameron J.S. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 10:(suppl 1):1990;81-87.
4. Williams P.S., Fass G., Bone J.M. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. QJM. 67:1988;343-354.
5. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329:1993;1456-1462.
6. Moorhead J.F. Lipids and progressive kidney disease. Kidney Int Suppl. 31:1991;S35-S40.
7. Keane W.F., Mulcahy W.S., Kasiske B.L., et al. Hyperlipidemia and progressive renal disease. Kidney Int Suppl. 31:1991;S41-S48.
8. Keane W.F. Lipids and the kidney. Kidney Int. 46:1994;910-920.
9. Sasaki T., Kurata H., Nomura K., et al. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med. 29:1990;156-163.
10. Rabelink A.J., Hene R.J., Erkelens D.W., et al. Partial remission of nephrotic syndrome in patient on long-term simvastatin. Lancet. 335:1990;1045-1046.
11. Shoji T., Nishizawa Y., Toyokawa A., et al. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron. 59:1991;664-665.
12. Sato H., Suzuki S., Ueno M., et al. Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int. 43:1993;430-435.
13. Kapelrud H., Bangstad H.J., Dahl-Jorgensen K., et al. Serum LP(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ. 303:1991;675-678.
14. Takegoshi T., Haba T., Hirai J., et al. Alterations of lipoprotein(a) in patients with diabetic nephropathy. Atherosclerosis. 83:1990;99-100.
15. Jerums G., Allen T.J., Tsalamandris C., et al. Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia. 36:1993;1037-1044.
16. Abe A., Noma A. Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis. 96:1992;1-8.
17. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 334:1996;939-945.
18. Parving H.H., Andersen A.R., Smidt U.M., Svendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1:1983;1175-1179.
19. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 285:1982;685-688.
20. Bakris G.L. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 112:1990;707-708.
21. Baba T., Murabayashi S., Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria a randomised controlled trial. Diabetologia. 32:1989;40-44.
22. Stornello M., Valvo E.V., Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 14:1989;851-855.
23. Nyberg G., Blohme G., Norden G. Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia. 30:1987;82-86.
24. Maeda S., Abe A., Seishima M., et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 78:1989;145-150.
25. Ledue T.B., Neveux L.M., Palomaki G.E., et al. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 223:1993;73-82.
26. Maroni B.J., Steinman T.I., Mitch W.E. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 27:1985;58-65.
27. Yukawa S., Mune M., Yamada Y., et al. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Int Suppl. 71:1999;S141-S143.
28. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 226:1989;271-276.
29. Seed M., O'Connor B., Perombelon N., et al. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. 101:1993;61-68.
30. Galle J., Stunz P., Schollmeyer P., Wanner C. Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells. Kidney Int. 47:1995;45-52.
31. Ishidoya S., Morrissey J., McCracken R., et al. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int. 47:1995;1285-1294.
32. Salonen E.M., Jauhiainen M., Zardi L., et al. Lipoprotein(a) binds to fibronectin and serine proteinase activity capable of cleaving it. EMBO J. 8:1989;4035-4040.
33. Funabiki K., Horikoshi S., Tomino Y., et al. Immunohistochemical analysis of extracellular components in the glomerular sclerosis of patients with glomerulonephritis. Clin Nephrol. 34:1990;239-246.
34. Samuelsson O., Attman P.O., Knight-Gibson C., et al. Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure. Nephrol Dial Transplant. 11:1996;2237-2243.
35. Kronenberg F., Trenkwalder E., Lingenhel A., et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 38:1997;1755-1763.
36. Black I.W., Wilcken D.E. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem. 38:1992;353-357.
37. Oida K., Takai H., Maeda H., et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem. 38:1992;2244-2248.
38. Carlson L.A., Levi L., Oro L. Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress, and their modification by nicotinic acid. J Clin Invest. 47:1968;1795-1805.